España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Enliven Therapeutics
ELVN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$22.50
-1.89
-7.75%
At close: -
$22.50
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Enliven Therapeutics (ELVN) Forecast
News
Earnings
Enliven Therapeutics (ELVN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics Stock (NASDAQ: ELVN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 13, 2024
BTIG Initiates Coverage On Enliven Therapeuti...
Benzinga Newsdesk
Friday, November 15, 2024
Baird Maintains Outperform on Enliven Therape...
Benzinga Newsdesk
Wednesday, November 13, 2024
Enliven Therapeutics Q3 2024 GAAP EPS $(0.48)...
Benzinga Newsdesk
Thursday, October 31, 2024
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Avi Kapoor
Jones Trading Initiates Coverage On Enliven T...
Benzinga Newsdesk
Monday, October 14, 2024
Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why
Zacks
Tuesday, October 01, 2024
HC Wainwright & Co. Reiterates Buy on Enliven...
Benzinga Newsdesk
Saturday, September 28, 2024
Enliven Therapeutics Announces Data Update Fr...
Benzinga Newsdesk
Thursday, September 19, 2024
Enliven Therapeutics shares are trading highe...
Benzinga Newsdesk
Wednesday, September 18, 2024
Enliven Therapeutics Announces Details Regard...
Benzinga Newsdesk
Monday, September 09, 2024
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Vandana Singh
HC Wainwright & Co. Initiates Coverage On Enl...
Benzinga Newsdesk
Tuesday, August 13, 2024
Enliven Therapeutics Q2 EPS $(0.41) Beats $(0...
Benzinga Newsdesk
Tuesday, June 11, 2024
Baird Initiates Coverage On Enliven Therapeut...
Benzinga Newsdesk
Tuesday, May 14, 2024
Enliven Therapeutics Q1 2024 Adj EPS $(0.54) ...
Benzinga Newsdesk
Thursday, April 11, 2024
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Vandana Singh
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
Enliven Therapeutics shares are trading highe...
Benzinga Newsdesk
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Enliven Therapeutics Announces Proof Of Conce...
Benzinga Newsdesk
Tuesday, April 09, 2024
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Vandana Singh
Mizuho Initiates Coverage On Enliven Therapeu...
Benzinga Newsdesk
Thursday, March 28, 2024
Enliven Therapeutics To Share Initial Proof O...
Benzinga Newsdesk
Tuesday, March 19, 2024
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Enliven Therapeutics shares are trading highe...
Benzinga Newsdesk
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Enliven Therapeutics Announces $90M Private P...
Benzinga Newsdesk
Thursday, March 14, 2024
Enliven Therapeutics Q4 EPS $(0.47) Beats $(0.54) Estimate
Happy Mohamed
Monday, February 26, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Tuesday, January 16, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Thursday, November 09, 2023
Enliven Therapeutics Q3 EPS $(0.51) Misses $(...
Benzinga Newsdesk
Friday, September 29, 2023
Enliven Therapeutics Insider Trades Send a Signal
Benzinga Insights
Tuesday, August 29, 2023
10% Owner At This Health Care Company Sells $7.04M of Stock
Benzinga Insights
Monday, August 14, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Thursday, August 10, 2023
Enliven Therapeutics, Inc. EPS $(0.41) Vs $(2...
Happy Mohamed
Wednesday, May 31, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Thursday, May 11, 2023
Enliven Therapeutics Q1 EPS $(0.80) Misses $(0.63) Estimate
Happy Mohamed
Wednesday, March 29, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Benzinga Insights
Jefferies Initiates Coverage On Enliven Thera...
Benzinga Newsdesk
Friday, March 03, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
Benzinga Insights
TD Cowen Initiates Coverage On Enliven Therap...
Benzinga Newsdesk
Tuesday, February 28, 2023
Enliven Therapeutics Chief Financial Officer Awarded $5.47M Worth of Stock Options
Benzinga Insights
Chief Scientific Officer at Enliven Therapeutics Acquires Company Stock Options Worth 433,081 Shares
Benzinga Insights
Enliven Therapeutics Chief Operating Officer Awarded $1.86M Worth of Stock Options
Benzinga Insights
Enliven Therapeutics Board Member Awarded $1.82M Worth of Stock Options
Benzinga Insights
Enliven Therapeutics Chief Medical Officer Awarded $5.99M Worth of Stock Options
Benzinga Insights
President and CEO at Enliven Therapeutics Acquires Company Stock Options Worth 748,913 Shares
Benzinga Insights
Enliven Therapeutics Director Awarded $430K Worth of Stock Options
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch